How to Check a Compounding Pharmacy Before You Buy

Before any database, ask the provider directly: "Which pharmacy will fill my prescription, and does it operate under 503A or 503B?" The answer itself is data. In our reviews, providers fall into three groups. They name it, with a licence number. Trimi publishes that its medications are compounded by state-licensed 503A pharmacies including VialsRx, Texas Board of Pharmacy #35264, and GreenwichRx, with a certificate of analysis available on request. That is a claim you can verify in five minutes. They name the pathway but not the pharmacy. Form Blends states its GLP-1s come from licensed 503A pharmacies. The Wellness Company states the dispensing pharmacy is assigned by state and identified on your prescription label — so you learn the name after you order, which is better than never. They say nothing at all. This is the largest group by far. Vios Compounding, Webster Pharmacy and Lititz Apothecary are actual compounding pharmacies that do not publish whether they are 503A or 503B — the single most important regulatory fact about them. A provider that refuses to name the pharmacy has failed the most basic transparency test available. That does not prove the product is bad. It does mean you cannot check.

Every pharmacy dispensing into your state must hold a licence, either in that state or as a non-resident pharmacy registered with your state's board. Where to look: your state board of pharmacy's online licence lookup, plus the board in the pharmacy's home state. Search by pharmacy name. The National Association of Boards of Pharmacy (NABP) maintains directory links to every state board. What it proves: the business is a licensed pharmacy in good standing, and whether there is any disciplinary history on file. Some boards publish disciplinary actions in the same lookup. What it does not prove: anything about sterility, potency, or how the medication is actually made. A licence is a floor, not a quality signal. This is the fastest check and the one that catches outright illegitimate operations.

This is the distinction that determines what rules govern your medication. Both are legal. They are not equivalent. 503A — a traditional compounding pharmacy. It prepares medications for an individual patient pursuant to a specific prescription, regulated by state boards of pharmacy under USP standards. It is not FDA-registered and is not routinely inspected by the FDA. 503B — an outsourcing facility. It registers with the FDA, operates under federal cGMP requirements, is subject to FDA inspection, and may compound in bulk without individual prescriptions. Most telehealth GLP-1 prescriptions are filled by 503A pharmacies — the less externally supervised of the two. Where to look: the FDA publishes a registered outsourcing facilities list. If a pharmacy claims 503B status, it should appear there. If it does not appear, it is a 503A regardless of how the marketing reads. Neither pathway produces an FDA-approved drug. A 503B facility is inspected; its output is still not an approved product.

Licensure is mandatory. Accreditation is voluntary, costs money, and requires an on-site assessment — which is why it carries more information. PCAB accreditation (Pharmacy Compounding Accreditation Board, part of ACHC) is the main one for compounding specifically. It covers sterile and non-sterile compounding separately, so check which the pharmacy holds. Accredited organisations are searchable on the accreditor's site. NABP Verified Pharmacy Program (VPP) involves an inspection and verification of licensure, and is searchable through NABP. LegitScript certification is used widely by online healthcare merchants and payment processors. LegitScript publishes a lookup for certified merchants. What good looks like. Pure Pharmacy is the most thoroughly documented compounder we have reviewed: PCAB accreditation for both sterile and non-sterile compounding, inspection under the NABP Verified Pharmacy Program, and third-party certification of its USP 795, 797 and 800 labs. Strive Pharmacy publishes 503A status alongside PCAB, NABP and LegitScript. What absent looks like. Vios, Webster and Lititz publish no accreditation at all. Again — not proof of a problem. But a pharmacy that has paid for an on-site assessment generally says so.

For a sterile injectable, this is the check that matters most, and it is where good pharmacies separate themselves sharply. Ask: "Is every sterile batch tested for sterility and endotoxins, and is product held until passing results are confirmed?" The relevant standards have names you can use: USP <71> — sterility testing. USP <85> — bacterial endotoxins testing. Pure Pharmacy states it performs USP 71 and USP 85 testing on all sterile products, runs in-house endotoxin testing on a Charles River EndoSafe system in addition to contracted third-party labs, and — the crucial part — that each sterile compound is submitted for third-party testing and is not dispensed until passing results are confirmed. That last commitment is the single most meaningful sentence a compounder can publish, because it means the pharmacy holds product rather than shipping and hoping. Very few publish it. Also ask for the beyond-use date (BUD) — how long your preparation remains valid. Strive publishes a 90-day BUD. A pharmacy that cannot tell you the BUD of the vial in your fridge is not tracking it for you. And ask for a certificate of analysis (COA) for your batch. Trimi states a COA is available on request. Reputable compounders can produce one.

The FDA publishes warning letters in a searchable public database, and separately announces recalls and compounding-related enforcement. Where to look: search the FDA warning letter database by company name. Also search the pharmacy name plus "recall" and plus "warning letter" generally, since state board actions do not appear in the FDA database. Why it is worth the five minutes: in our review of Empower Pharmacy we documented FDA warning letters from 2017 and subsequent enforcement references. That is public information a customer would never learn from a telehealth provider's website. One caution from our own research. When we reviewed CB2, the first BBB profile we found was a San Francisco store-location record marked "no longer in business" since February 2023 — while the corporate profile in Northbrook was A+. Dead location records and similarly-named entities are common. Match the legal entity name and address, not just the brand, before you conclude anything.

Put the five checks together and most providers sort themselves quickly. You are not looking for perfection. You are looking for whether the company will let you verify anything at all. A pharmacy that publishes its pathway, its accreditations and its release-testing policy is inviting scrutiny. One that publishes none of it is asking for trust it has not earned.

Before you spend twenty minutes vetting a compounding pharmacy, spend five checking whether you need one. The economics changed in 2026. LillyDirect sells FDA-approved Zepbound self-pay at $299 (2.5 mg) rising to $699 (10–15 mg). NovoCare Pharmacy sells Wegovy at $199 for the pen and $149 for the tablet, or as little as $25/month with commercial insurance. Eligible Medicare Part D patients may pay no more than $50/month for Zepbound through the Medicare GLP-1 Bridge. Compounded programs in our reviews run roughly $89 to $499 a month. When the approved drug and the compounded copy cost about the same, every one of the five checks above becomes unnecessary — because an FDA-approved product has already been reviewed for safety, effectiveness and manufacturing quality, and the dose in the pen is the dose that was studied. There are still legitimate reasons to use compounded medication: a dose or formulation that is not commercially available, a documented allergy to an excipient, or a price gap that is genuinely large in your circumstances. "It is cheaper" is not automatically one of them any more. Run the comparison at the dose you would actually be maintained on, not the starting dose.